COMMUNIQUÉS West-GlobeNewswire

Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
14/11/2025
REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the [...]
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
14/11/2025
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing [...]
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
14/11/2025
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Femasys Announces Third Quarter Financial Results for 2025
14/11/2025
– FDA Approval to Advance Final FemBloc ® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE [...]
TOMI Environmental Solutions, Inc. Reports Q3 2025 Financial Results and Outlines Growth Initiatives
14/11/2025
FREDERICK, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® ( [...]
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
14/11/2025
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
14/11/2025
– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment [...]
Biogen Completes Acquisition of Alcyone Therapeutics
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
4DMT Announces New Employment Inducement Grants
14/11/2025
EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
14/11/2025
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular [...]
Health Catalyst to Participate in Upcoming Investor Conferences
14/11/2025
SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]
PetVivo Reports Fiscal Q2 2026 Results with Revenues up 50%
14/11/2025
MINNEAPOLIS, MN, US, Nov. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTC ID: PETVW), through its wholly owned subsidiary Petvivo Animal Health, a leading biomedical company delivering innovative [...]
Precipio Announces its Q3-2025 Financial Results
14/11/2025
Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter NEW HAVEN, Conn., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , filed its [...]
BiomX Inc. Announces 1-for-19 Reverse Stock Split
14/11/2025
NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific [...]
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
14/11/2025
MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel [...]
Avadel Receives Unsolicited Proposal from Lundbeck
14/11/2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION [...]
New study finds half of young men at risk of problem anger
14/11/2025
VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- New research from the Canadian Men’s Health Foundation (CMHF) reveals half of Canadian men aged 19–29 are at risk of problem anger—when anger interferes [...]
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
14/11/2025
Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10 [...]

Pages